Mr. Adam Peeler reports

PHARMACORP CLOSES PREVIOUSLY ANNOUNCED ONTARIO PHARMACY ACQUISITION AND PROVIDES UPDATE

Further to Pharmacorp Rx Inc.'s May 25, 2026, news release, it has completed the acquisition of a 100-per-cent interest in a PharmaChoice Canada-bannered pharmacy located in Ontario.

• Purchase price of approximately $8.1-million;
• Acquisition increases Pharmacorp's operating network to 15 pharmacies;
• Previously announced second definitive share purchase agreement has received preliminary college approval and is anticipated to close on or about Aug. 17, 2026;
• Additional non-binding letter of intent executed for a proposed pharmacy acquisition in Western Canada.

The acquisition represents the 10th pharmacy added to the corporation's operating network through acquisitions completed since August, 2025, and increases Pharmacorp's overall store count to 15 pharmacies.

The aggregate purchase price for the acquisition was approximately $8.1-million and was financed using the corporation's existing cash resources. The pharmacy was acquired from an arm's-length vendor group, and no finders' fees were payable in connection with the acquisition.

In its April 30, 2026, news release, Pharmacorp disclosed that it had executed four non-binding letters of intent, dated Feb. 23, 2026, Feb. 27, 2026, March 3, 2026, and March 23, 2026, respectively, relating to four additional proposed pharmacy acquisitions.

Since that announcement, the corporation has entered into definitive share purchase agreements in respect of two of the four letters of intent, one of which relates to the acquisition announced today and one of which relates to a PharmaChoice Canada-bannered pharmacy located in Western Canada.

The acquisition announced today is the first of the definitive agreements to close.

The corporation has received preliminary approval from the applicable provincial college of pharmacy in respect of the second definitive agreement and anticipates closing on or about Aug. 17, 2026, subject to the satisfaction or waiver of customary closing conditions. If completed, that acquisition would increase Pharmacorp's overall store count to 16 pharmacies.

Following the conversion of two of the four previously announced letters of intent into the definitive agreements, the two remaining previously announced non-binding letters of intent are progressing toward definitive purchase agreements. In addition, the corporation has executed a further non-binding letter of intent, dated July 23, 2026, relating to the proposed acquisition of a pharmacy located in Western Canada.

Together with the previously disclosed non-binding letter of intent dated June 23, 2026, Pharmacorp currently has four active non-binding letters of intent in process. The proposed acquisitions contemplated by the active letters of intent remain subject to completion of due diligence and the negotiation and execution of definitive purchase agreements.

About Pharmacorp Rx Inc.

Pharmacorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. Through a combination of capital, strategic support and operational expertise, Pharmacorp is building a national network of community pharmacies under the PharmaChoice Canada banner.

Pharmacorp currently operates 15 PharmaChoice Canada-bannered pharmacies and intends to continue acquiring both PharmaChoice Canada-bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform in accordance with its strategic alliance with PharmaChoice Canada, where applicable. Pharmacorp shares trade on the TSX Venture Exchange under the symbol PCRX.

Pharmacorp welcomes discussions with pharmacy owners considering succession or sale.

We seek Safe Harbor.